MK-0608

• Description:

  MK-0608 is a potent and orally bioavailable inhibitor of HCV replication in vitro with an EC50 of 0.3 μM (EC90=1.3 μM) in the subgenomic-replicon assay[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  HCV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/mk-0608.html

• Purity:

  99.81

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  OC[C@@H]1[C@@H] (O) [C@] (O) (C) [C@H] (N2C=CC3=C2N=CN=C3N) O1

• Molecular Formula:

  C12H16N4O4

• Molecular Weight:

  280.28

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Carroll SS, et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother. 2009 Mar;53 (3) :926-34.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  443642-29-3